174 related articles for article (PubMed ID: 34956360)
1. p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for
Li J; Wang J; Su D; Nie X; Liu Y; Teng L; Pang J; Wu H; Liang Z
Gastroenterol Res Pract; 2021; 2021():2510195. PubMed ID: 34956360
[TBL] [Abstract][Full Text] [Related]
2. Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma.
Li X; Luo D; Zhang L; Li Q; Fan J; Zhang J; Huang B; Yang M; Nie X; Chang X; Pan H
BMC Cancer; 2023 Oct; 23(1):1008. PubMed ID: 37858047
[TBL] [Abstract][Full Text] [Related]
3. Optimized p53 immunohistochemistry is an accurate predictor of
Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
[No Abstract] [Full Text] [Related]
4. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
[TBL] [Abstract][Full Text] [Related]
5. p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations.
Sung YN; Kim D; Kim J
Diagn Pathol; 2022 Dec; 17(1):92. PubMed ID: 36471402
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
[TBL] [Abstract][Full Text] [Related]
7. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?
Dinu A; Aschie M; Cozaru GC; Mitroi AF; Grasa CN; Iordache IE; Deacu M; Orasanu CI; Nicolau AA; Baltatescu GI
J Gastrointestin Liver Dis; 2023 Jun; 32(2):162-169. PubMed ID: 37345605
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations of GI-NECs involving three main signaling pathways.
Dai Q; Zhang J; Long W; Haybaeck J; Yang Z
Cancer Med; 2023 Apr; 12(7):8238-8250. PubMed ID: 36653904
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.
Yang G; Anderson Williams S; He F; He Y; McIntyre K; Beckman AK; Nelson AC; Yohe SL
Pathology; 2024 Apr; 56(3):404-412. PubMed ID: 38341302
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
[TBL] [Abstract][Full Text] [Related]
11. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer.
Hwang HJ; Nam SK; Park H; Park Y; Koh J; Na HY; Kwak Y; Kim WH; Lee HS
J Pathol Transl Med; 2020 Sep; 54(5):378-386. PubMed ID: 32601264
[TBL] [Abstract][Full Text] [Related]
12. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
[No Abstract] [Full Text] [Related]
13. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
Am J Surg Pathol; 2023 Oct; 47(10):1144-1150. PubMed ID: 37528644
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical staining patterns of p53 predict the mutational status of TP53 in oral epithelial dysplasia.
Sawada K; Momose S; Kawano R; Kohda M; Irié T; Mishima K; Kaneko T; Horie N; Okazaki Y; Higashi M; Tamaru JI
Mod Pathol; 2022 Feb; 35(2):177-185. PubMed ID: 34404905
[TBL] [Abstract][Full Text] [Related]
15. p53 protein expression patterns associated with TP53 mutations in breast carcinoma.
Anderson SA; Bartow BB; Harada S; Siegal GP; Wei S; Dal Zotto VL; Huang X
Breast Cancer Res Treat; 2024 Jun; ():. PubMed ID: 38900212
[TBL] [Abstract][Full Text] [Related]
16. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
17. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
Köbel M; Kang EY
Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
[TBL] [Abstract][Full Text] [Related]
18. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.
Rindi G; Mete O; Uccella S; Basturk O; La Rosa S; Brosens LAA; Ezzat S; de Herder WW; Klimstra DS; Papotti M; Asa SL
Endocr Pathol; 2022 Mar; 33(1):115-154. PubMed ID: 35294740
[TBL] [Abstract][Full Text] [Related]
19. Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.
de Haan LM; de Groen RAL; de Groot FA; Noordenbos T; van Wezel T; van Eijk R; Ruano D; Diepstra A; Koens L; Nicolae-Cristea A; Hartog WCED; Terpstra V; Ahsmann E; Dekker TJA; Sijs-Szabo A; Veelken H; Cleven AHG; Jansen PM; Vermaat JSP
Virchows Arch; 2023 Oct; ():. PubMed ID: 37851120
[TBL] [Abstract][Full Text] [Related]
20. P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation.
Trias I; Saco A; Marimon L; López Del Campo R; Manzotti C; Ordi O; Del Pino M; Pérez FM; Vega N; Alós S; Martínez A; Rodriguez-Carunchio L; Reig O; Jares P; Teixido C; Ajami T; Corral-Molina JM; Algaba F; Ribal MJ; Ribera-Cortada I; Rakislova N
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
